{"preliminary_commentary":{"by_channel":{"x_thread":2,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":"relapsed or refractory multiple myeloma","name":"TriPRIL","nct_id":"NCT05020444","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=tripril-nct05020444. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Prior to receiving TriPRIL CAR T Cells, participants will undergo two preparatory processes:\n\n* Leukapheresis: White blood cells will be collected and manufacture TriPRIL CAR T cells at a GMP manufacturing facility.\n* Lymphodepletion: On days, -5, -4. -3 participants will receive 3 days of chemotherapy to decrease the number of lymphocytes\n\nTriPRIL CAR T Cells will be administered intravenously on day 0 using a 3+3 dose escalation design","label":"TriPRIL CAR T Cells-Dose Escalation","type":"EXPERIMENTAL"},{"description":"Prior to receiving TriPRIL CAR T Cells, participants will undergo two preparatory processes:\n\n* Leukapheresis: White blood cells will be collected and manufacture TriPRIL CAR T cells at a GMP manufacturing facility.\n* Lymphodepletion: On days, -5, -4. -3 participants will receive 3 days of chemotherapy to decrease the number of lymphocytes\n\nTriPRIL CAR T Cells will be administered intravenously on day 0 using the respective dose (at or below the Maximum Tolerated Dose-MTD), as determined during the dose escalation part.","label":"TriPRIL CAR T Cells-Dose Expansion","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2028-02-24","type":"ESTIMATED"},"conditions":["Multiple Myeloma","Multiple Myeloma in Relapse","Refractory Multiple Myeloma"],"enrollment":{"count":16,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"TriPRIL CAR T Cells","otherNames":[],"type":"DRUG"},{"name":"Cyclophosphamide","otherNames":["Cytoxan","Neosar"],"type":"DRUG"},{"name":"Fludarabine","otherNames":["Fludara"],"type":"DRUG"}],"last_update":"2026-08-07","lead_sponsor":"Marcela V. Maus, M.D.,Ph.D.","official_title":"A Phase I Clinical Trial With TriPRIL CAR T Cells for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2028-02-24","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Incidence of adverse events (AEs)","timeFrame":"Week 24 post dosing, and every three months until two years."},{"measure":"Incidence of Dose Limiting Toxicity (DLT)","timeFrame":"Week 24 post dosing, and every three months until two years."}],"references":[],"start_date":{"date":"2021-10-05","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"TriPRIL CAR T Cells in Multiple Myeloma","url":"https://clinicaltrials.gov/study/NCT05020444"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/tripril-nct05020444"}